The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results.
 
Baukelien Van Triest
No Relationships to Disclose
 
Lars Damstrup
Employment - Merck KGaA
Patents, Royalties, Other Intellectual Property - Merck KGaA
Travel, Accommodations, Expenses - Merck KGaA
 
Johan Falkenius
No Relationships to Disclose
 
Volker Budach
No Relationships to Disclose
 
Esther Troost
No Relationships to Disclose
 
Michael Samuels
No Relationships to Disclose
 
Juergen Debus
No Relationships to Disclose
 
Morten Mau Sørensen
No Relationships to Disclose
 
Karin Berghoff
Employment - Merck KGaA
 
Rainer Strotman
No Relationships to Disclose
 
Mark van Bussel
No Relationships to Disclose
 
Sanjay Goel
Research Funding - Oncolytics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Poul F. Geertsen
No Relationships to Disclose